Mosaic ImmunoEngineering (CPMV) Change in Account Payables (2020 - 2026)
Mosaic ImmunoEngineering (CPMV) posted quarterly Change in Account Payables of $34274.0 for Q1 2026, up 950.06% year-over-year from $3264.0 in Q1 2025, and up 3615.28% quarter-over-quarter from -$975.0 in Q4 2025.
Mosaic ImmunoEngineering (CPMV) Change in Account Payables (2020 - 2026) Analysis & Trends
Mosaic ImmunoEngineering's Change in Account Payables history runs 7 years deep, the most recent figure standing at $34274.0 for Q1 2026.
- In Q1 2026, Change in Account Payables rose 950.06% year-over-year to $34274.0; the TTM figure through Mar 2026 stood at $28929.0 (up 220.06% YoY), while the FY2025 annual figure was -$2081.0, up 87.3% from the prior year.
- Change in Account Payables for Q1 2026 stood at $34274.0, up from -$975.0 in the prior quarter.
- The five-year high for Change in Account Payables was $34274.0 in Q1 2026, with the low at -$41527.0 in Q4 2024.
- The 5-year median for Change in Account Payables is -$49.0 (2025), against an average of $1221.8.
- The sharpest annual moves came in 2022 and 2024: Change in Account Payables jumped 1655.68% in 2022, then sank 2118.81% in 2024.
- Mosaic ImmunoEngineering's Change in Account Payables stood at $12181.0 in 2022, then plunged by 83.11% to $2057.0 in 2023, then tumbled by 2118.81% to -$41527.0 in 2024, then jumped by 97.65% to -$975.0 in 2025, then soared by 3615.28% to $34274.0 in 2026.
- Business Quant data shows CPMV's Change in Account Payables at $34274.0 in Q1 2026, -$975.0 in Q4 2025, and -$49.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Mosaic ImmunoEngineering | 3.68 Mn | 3.68 Mn | - | 34,274.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 34,274.00 |
| Mar 31, 2026 | 34,274.00 |
| Dec 31, 2025 | -975.00 |
| Dec 31, 2025 | -975.00 |
| Sep 30, 2025 | -49.00 |
| Sep 30, 2025 | -49.00 |
| Jun 30, 2025 | -4,321.00 |
| Jun 30, 2025 | -4,321.00 |
| Mar 31, 2025 | 3,264.00 |
| Mar 31, 2025 | 3,264.00 |
| Dec 31, 2024 | -41,527.00 |
| Dec 31, 2024 | -41,527.00 |
| Sep 30, 2024 | 18,578.00 |
| Sep 30, 2024 | 18,578.00 |
| Jun 30, 2024 | -4,411.00 |
| Jun 30, 2024 | -4,411.00 |
| Mar 31, 2024 | 10,973.00 |
| Mar 31, 2024 | 10,973.00 |
| Dec 31, 2023 | 2,057.00 |
| Dec 31, 2023 | 2,057.00 |